Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.21.2
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Expenses    
Research and development $ 11,815 $ 3,630
General and administrative 9,757 4,514
Merger costs 500 1,054
In-process research and development 16,094  
Operating expenses (38,166) (9,198)
Other income (loss)    
Foreign exchange (12) (3)
Amortization of deferred loan costs (94)  
Interest - net (26) 75
Other loss (income) (132) 72
Net loss for the year (38,298) (9,126)
Computation of basic loss per share    
Net loss for the year (38,298) (9,126)
Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance (3,181)  
Series A Preferred cash dividend (8) (8)
Series B Preferred stock dividend (17) (9)
Net loss for the year attributable to common stockholders $ (41,504) $ (9,143)
Basic and fully diluted loss per share $ (1.60) $ (0.87)
Basic and fully diluted weighted average number of shares 25,886,000 10,444,000